Syngene International IPO oversubscribed 31 times
The IPO is an offer for sale (OFS) by Biocon of a part of its shareholding in Syngene Syngene International's (Syngene) Initial…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Biocon
Syngene International gets RoC approval for its RHP
The price band for the offer has been fixed between Rs 240 and Rs. 250 per equity share of Rs 10 each
Kiran Mazumdar Shaw ranked No. 2 in Global ‘Medicine Maker Power List’ 2015
She is the only India-based business leader featuring on the list
Kiran Mazumdar-Shaw ranked No. 2 in Global ‘Medicine Maker Power List’ 2015
She is the only India based business leader featuring on the list
Biocon-Mylan programmes make clinical progress
PEG-G-CSF and Adalimumab enter phase II while patient recruitment for one insulin Glargine phase II study is complete Biocon has…
Biocon top line grows 15 per cent in Q4 FY15
Research services subsidiary Syngene delivers 27 per cent growth
Syngene seeks approval for IPO, files DRHP
Offer allows Biocon to monetise its shareholding in Syngene
ABLE elects new office bearers
To focus on improved strategies to catapult the industry to new heights
Biocon receives approval for Insulin Glargine in Mexico through its partner PiSA Farmaceutica
The combined market for Insulin Glargine in Mexico is estimated to be in excess of $40 million